SCHEDULE 13D/A 0001640809 XXXXXXXX LIVE 7 Common Stock, par value $0.001 per share 05/27/2025 true 0001005286 514766104 Lifecore Biomedical, Inc.

3515 Lyman Boulevard Chaska MN 55318

Aron R. English, 22NW, LP (206) 227-3078 590 1st Avenue S Unit C1 Seattle WA 98104 0001640809 N 22NW Fund, LP a WC N DE 2975398 0 2975398 0 2975398 N 7.49 PN Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company. Percentage is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. 0001694297 N 22NW, LP a OO N DE 2975398 0 2975398 0 2975398 N 7.49 PN Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company. Percentage is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. 0001770575 N 22NW Fund GP, LLC a OO N DE 2975398 0 2975398 0 2975398 N 7.49 OO Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company. Percentage is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. 0001783663 N 22NW GP, Inc. a OO N DE 2975398 0 2975398 0 2975398 N 7.49 CO Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company. Percentage is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. 0001770436 N Aron R. English a OO N X1 2975398 0 2975398 0 2975398 N 7.49 IN Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Company. Percentage is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. 0001888106 N Bryson O. Hirai-Hadley a PF N X1 583 0 583 0 583 N 0 IN 0001952771 N Nathaniel Calloway a OO N X1 0 0 0 0 0 N 0 IN Common Stock, par value $0.001 per share Lifecore Biomedical, Inc. 3515 Lyman Boulevard Chaska MN 55318 The following constitutes Amendment No. 7 ("Amendment No. 7") to the Schedule 13D filed by the undersigned on January 10, 2023, as previously amended on June 28, 2023, February 29, 2024, May 20, 2024, June 11, 2024, July 1, 2024 and December 26, 2024 (as amended, the "Schedule 13D"). This Amendment No. 7 amends the Schedule 13D as specifically set forth herein. Items 5(a) - (b) are hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based upon 39,736,549 Shares outstanding, consisting of (i) 37,025,331 shares of Common Stock as of March 27, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 3, 2025, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock. As of the date hereof, 22NW Fund directly beneficially owned 2,975,398 Shares, including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock, constituting approximately 7.49% of the Shares outstanding. As of the date hereof, Mr. Hirai-Hadley directly beneficially owned 583 Shares, constituting less than 1% of the Shares outstanding. By virtue of his position as a partner of 22NW, Mr. Hirai-Hadley may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. As of the date hereof, Mr. Calloway directly beneficially owned zero Shares, constituting less than 0% of the Shares outstanding. By virtue of his position as a partner of 22NW, Mr. Calloway may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. 22NW, as the investment manager of 22NW Fund, may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. 22NW GP, as the general partner of 22NW Fund, may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. 22NW Inc., as the general partner of 22NW, may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. Mr. English, as the portfolio manager of 22NW, manager of 22NW GP and president and sole shareholder of 22NW Inc., may be deemed to beneficially own the 2,975,398 Shares beneficially owned by 22NW Fund, constituting approximately 7.49% of the Shares outstanding. Each Reporting Person may be deemed to be a member of a "group" with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and such group may be deemed to beneficially own the 2,975,398 Shares owned in the aggregate by all of the Reporting Persons, constituting approximately 7.49% of the outstanding Shares. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own. In the past sixty days, 22NW Fund, LP sold 1,490,981 shares of the Issuer's common stock in the aggregate in the open market. Attached as Schedule A is a chart including the date of the transaction, the number of shares sold, and the weighted average price of the shares sold in the past sixty days. 22NW Fund, LP /s/ Aron R. English 05/29/2025 22NW, LP /s/ Aron R. English 05/29/2025 22NW Fund GP, LLC /s/ Aron R. English 05/29/2025 22NW GP, Inc. /s/ Aron R. English 05/29/2025 Aron R. English /s/ Aron R. English 05/29/2025 Bryson O. Hirai-Hadley /s/ Bryson O. Hirai-Hadley 05/29/2025 Nathaniel Calloway /s/ Aron R. English 05/29/2025